1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 Apr 2024
Admin
News Article

AriBio Granted EMA Authorization for Phase 3 Clinical Trial of AR1001

AriBio Granted EMA Authorization for Phase 3 Clinical Trial of AR1001 in Alzheimer’s Treatment (POLARIS-AD)

Overview

AriBio Co., Ltd. (AriBio) has received approval from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a phase 3 clinical trial targeting early Alzheimer’s disease. This approval aligns with similar authorizations from the U.S. Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the trial.

Approval for Member States

EMA's decision, finalized on April 24th, grants approval for the trial to proceed in several member states including the Czech Republic, Denmark, France, Germany, Italy, Spain, and The Netherlands.
The trial aims to enroll 1,150 participants across 200 sites worldwide.

POLARIS-AD

POLARIS-AD is a significant trial evaluating the efficacy and safety of AR1001 (Mirodenafil) in treating early Alzheimer’s disease with confirmed amyloid pathology.
It employs primary and secondary endpoints accepted by FDA and EMA, including the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB) and several others.

AriBio on Efficient Trial

AriBio, expressed satisfaction with the trial's expansion into additional European countries, viewing it as a milestone in AR1001's registration program.
He emphasized the company's dedication to efficiently expand the trial into these regions to meet the demand for alternative Alzheimer’s treatments.
The global nature of the trial enhances accessibility to the treatment if its efficacy and safety are demonstrated.

About AR1001

AR1001 is a phosphodiesterase-5 (PDE5) inhibitor under investigation as an oral agent for Alzheimer’s disease treatment.
Pre-clinical studies suggest it may offer neuroprotective effects by inhibiting neuron apoptosis and restoring synaptic plasticity, indicating potential disease-modifying effects.

About Trial

The trial, AR1001-ADP3-US01 (NCT05531526), is a phase 3 double-blind, randomized, placebo-controlled, multi-center trial evaluating AR1001 in early Alzheimer’s disease patients.
More information about the trial is available on ClinicalTrials.gov.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!